Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 351 to 400 of 2065 results for work

  1. Eating disorders: recognition and treatment (NG69)

    This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.

  2. Accessibility changes: notes for developers (ECD6)

    This document summarises the most common accessibility changes NICE is making in guidelines, and why

  3. Elafibranor for previously treated primary biliary cholangitis (TA1016)

    Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.

  4. Meetings in public

    Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.

  5. Interim methods guide for developing good practice guidance (PMG15)

    This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance

  6. Sickle cell disease: managing acute painful episodes in hospital (CG143)

    This guideline covers managing acute painful sickle cell episodes in children, young people and adults who present at hospital, from presentation until when they are discharged. It aims to reduce variation in how acute episodes are managed in hospital, focusing on effective, prompt and safe pain relief.

  7. Dapagliflozin for treating chronic kidney disease (TA1075)

    Evidence-based recommendations on dapagliflozin for treating chronic kidney disease in adults.

  8. Attention deficit hyperactivity disorder: diagnosis and management (NG87)

    This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.

  9. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.

  10. Forward view - our priority topics

    Our forward view highlights the topics we will prioritise in the coming year.

  11. Intermediate care including reablement (QS173)

    This quality standard covers referral and assessment for intermediate care and how to deliver the service. It covers bed-based intermediate care, crisis response, home-based intermediate care and reablement. It describes high-quality care in priority areas for improvement. It does not cover rehabilitation for specific conditions.

  12. Types of recommendation NICE can make

    NICE makes 4 types of recommendation that allow us to produce clear, directive, actionable guidance that is easy to understand and put into practice.

  13. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development Reference number: GID-TA11140 Expected publication date: TBC

  14. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  15. Developing NICE guidelines: the manual (PMG20)

    This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE

  16. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date:  25 February 2026

  17. Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

    Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.

  18. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for stress urinary incontinence – Options for women referred to specialist centres

    general mobility. If you decide to have surgery, your physiotherapist will work with you before and after the operation to enhance your...

  19. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for pelvic organ prolapse – Options for women referred to specialist centres

    general mobility. If you decide to have surgery, your physiotherapist will work with you before and after the operation to enhance your...

  20. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

  21. Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

    Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.

  22. Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment (HTG753)

    Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults.

  23. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

  24. Routine preoperative tests for elective surgery (NG45)

    This guideline covers routine preoperative tests for people aged over 16 who are having elective surgery. It aims to reduce unnecessary testing by advising which tests to offer people before minor, intermediate and major or complex surgery, taking into account specific comorbidities (cardiovascular, renal and respiratory conditions and diabetes and obesity). It does not cover pregnant women or people having cardiothoracic procedures or neurosurgery.

  25. Renal and ureteric stones (QS195)

    This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.

  26. NICE indicator process guide (PMG44)

    This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance and NICE accredited sources

  27. Topic engagement

    a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Support a quality standard...

  28. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  07 May 2026

  29. Freedom of information publication scheme

    Finder website . You can register there to receive email alerts about the work that NICE is tendering for. What are our priorities and...

  30. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

  31. Help implement NICE guidance

    a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Help us improve Help...

  32. Standards and indicators

    We have a library of over 200 quality standards and a single menu of indicators, designed to help define and measure quality in health, public health and social care.

  33. Fractures (complex): assessment and management (NG37)

    This guideline covers assessing and managing pelvic fractures, open fractures and severe ankle fractures (known as pilon fractures and intra-articular distal tibia fractures) in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It aims to reduce deaths and long-term health problems by improving the quality of emergency and urgent care.

  34. Drug misuse prevention: targeted interventions (NG64)

    This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.

  35. Mental health problems in people with learning disabilities: prevention, assessment and management (NG54)

    This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.

  36. Tinnitus: assessment and management (NG155)

    This guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. It offers advice to healthcare professionals on supporting people presenting with tinnitus and on when to refer for specialist assessment and management.

  37. Older people: independence and mental wellbeing (NG32)

    This guideline covers interventions to maintain and improve the mental wellbeing and independence of people aged 65 or older and how to identify those most at risk of a decline.

  38. Sexual health (QS178)

    This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.

  39. Trauma (QS166)

    This quality standard covers assessing and managing trauma (complex fractures, non-complex fractures, major trauma and spinal injury) in adults, young people and children. It describes high-quality care in priority areas for improvement.

  40. NICE Health Technology Assessment training programme

    We offer a dedicated training opportunity to achieve competency in curriculum outcome KA7.5.

  41. NICE Health Technology Assessment training programme

    We offer a dedicated training opportunity to achieve competency in curriculum outcome KA7.5.

  42. Our committees

    NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers. Your involvement is highly valued. We are guided by your knowledge and experience.

  43. In-depth

    "item":{"name":"In-depth"}}]} In-depth Our in-depth articles explore how our work is making a real difference to people's lives. Through...

  44. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTG695)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.

  45. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

  46. Healthy start vitamins: special report on cost effectiveness (ECD5)

    This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering

  47. Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)

    This quality standard covers recognition, early intervention and long-term management of bipolar disorder, psychosis and schizophrenia in children and young people (under 18). It also includes support for parents and carers. It describes high-quality care in priority areas for improvement.

  48. Quality standard consultations

    a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Support a quality standard...

  49. Drug misuse prevention (QS165)

    This quality standard covers the prevention or delay of harmful use of drugs by children, young people and adults most likely to start using drugs, or already experimenting or using drugs occasionally. This includes illegal psychoactive substances, solvents, volatile substances, image- and performance-enhancing drugs, prescription-only medicines and over-the-counter medicines. It describes high-quality care in priority areas for improvement.

  50. Head injury (QS74)

    This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for improvement.